Mohamed Sorror

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:961-8. 2004
  2. ncbi Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
    Andrew R Rezvani
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
    J Clin Oncol 26:211-7. 2008
  3. pmc Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center
    Mediterr J Hematol Infect Dis 2:e2010015. 2010
  4. pmc How I assess comorbidities before hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA
    Blood 121:2854-63. 2013
  5. pmc Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 111:446-52. 2008
  6. ncbi Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 25:4246-54. 2007
  7. pmc Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109 1024, USA
    Blood 110:4606-13. 2007
  8. doi Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
    Mohamed Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer 112:1992-2001. 2008
  9. pmc Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 26:4912-20. 2008
  10. doi Comorbidities and hematopoietic cell transplantation outcomes
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109, USA
    Hematology Am Soc Hematol Educ Program 2010:237-47. 2010

Research Grants

Detail Information

Publications38

  1. ncbi Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:961-8. 2004
    ..After adjustment for pretransplantation differences between the 2 patient groups, the hazard ratio was 3.0 (P=.04). Multivariate analyses showed higher pretransplantation comorbidity scores to result in increased toxicity and mortality...
  2. ncbi Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
    Andrew R Rezvani
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
    J Clin Oncol 26:211-7. 2008
    ..Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting...
  3. pmc Role of comorbidities in optimizing decision-making for allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center
    Mediterr J Hematol Infect Dis 2:e2010015. 2010
    ..Here, we describe this development and illustrate the usefulness of the HCT-CI in predicting HCT outcomes in patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation...
  4. pmc How I assess comorbidities before hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA
    Blood 121:2854-63. 2013
    ..89 to 0.97. This proposed training program will facilitate reliable assessment of comorbidities in the clinic and for research studies leading to standardization of the use of comorbidities in prediction of HCT outcomes...
  5. pmc Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 111:446-52. 2008
    ..01). Patients without comorbidities could be enrolled in prospective randomized studies comparing different conditioning intensities. Younger patients with comorbidities might benefit from reduced conditioning intensity...
  6. ncbi Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 25:4246-54. 2007
    ..Refined risk stratification is required to design prospective trials...
  7. pmc Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109 1024, USA
    Blood 110:4606-13. 2007
    ..98, P = .94). The HCT-CI is a sensitive and informative tool for comparing trial results at different institutions. Inclusion of comorbidity data in HCT trials provides valuable, independent information...
  8. doi Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
    Mohamed Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer 112:1992-2001. 2008
    ..Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS)...
  9. pmc Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 26:4912-20. 2008
    ..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients...
  10. doi Comorbidities and hematopoietic cell transplantation outcomes
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109, USA
    Hematology Am Soc Hematol Educ Program 2010:237-47. 2010
    ..Future knowledge of the impacts of multiple comorbidities on post-HCT toxicities might guide new prophylactic and therapeutic interventions to lessen the procedure's mortality...
  11. pmc Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
    Mohamed L Sorror
    Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    JAMA 306:1874-83. 2011
    ..A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions...
  12. ncbi Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
    J Clin Oncol 24:4150-7. 2006
    ..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches...
  13. pmc Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts
    Boglarka Gyurkocza
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 15:1314-22. 2009
    ..We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI...
  14. pmc Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
    Andrew R Rezvani
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Br J Haematol 143:395-403. 2008
    ..Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT...
  15. ncbi Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 23:1993-2003. 2005
    ..This approach relied on graft-versus-tumor (GVT) effects for control of malignancy...
  16. ncbi Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 23:3819-29. 2005
    ..The aim of this study was to analyze the outcome of patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell transplantation (HCT)...
  17. ncbi Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:355-65. 2007
    ..04), and decreased comorbidity score (P = .03) remained statistically significant for improved survival. Our findings show that hematopoietic cell transplantation offers potentially curative treatment for patients with ICMF, PV, or ET...
  18. pmc A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients
    Meagan J Bemer
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Chemother Pharmacol 72:607-18. 2013
    ....
  19. ncbi Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation
    Frederic Baron
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:813-7. 2006
    ..Additional immunosuppression with pentostatin did not improve that outcome. The model might be useful in developing potential strategies aimed at preventing graft rejection in patients with low donor chimerism levels...
  20. pmc Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 120:1398-408. 2012
    ..Although mortality declined significantly in recent years, novel strategies are needed to overcome the barrier of high-risk cytogenetics...
  21. ncbi Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:713-20. 2005
    ..D. Anderson prognostic score. The data suggest that patients with few or no comorbidities and those who undergo transplantation earlier in the disease course have the highest probability of successful outcome after allogeneic HCT...
  22. ncbi What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?
    Razvan Diaconescu
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:335-44. 2005
    ..82 (P = .09). We concluded that administering ATG before an otherwise suboptimal conditioning dose of 1 Gy of TBI failed to secure uniform stable hematopoietic engraftment...
  23. ncbi Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
    Razvan Diaconescu
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 104:1550-8. 2004
    ..In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores...
  24. pmc Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
    Marcello Rotta
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:3383-91. 2009
    ..03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues...
  25. pmc Reduced mortality after allogeneic hematopoietic-cell transplantation
    Ted A Gooley
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 363:2091-101. 2010
    ..Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation...
  26. pmc Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 29:1190-7. 2011
    ..Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD)...
  27. pmc Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas
    Andrei R Shustov
    University of Washington, Seattle, WA, USA
    Br J Haematol 150:170-8. 2010
    ..These results suggest that graft-versus-T-cell lymphoma activity is responsible for long-term disease control...
  28. pmc Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:2912-9. 2005
    ..In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT...
  29. pmc Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1499-507. 2007
    ..We conclude that within the limitations of a retrospective study, these results indicate that candidates for nonmyeloablative HCT without suitable related donors may expect similar outcomes with grafts from URDs...
  30. pmc Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 13:423-32. 2007
    ....
  31. doi Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Transplantation 85:1023-9. 2008
    ..Late graft rejection after conditioning with 1 Gy of total body irradiation (TBI) was consistently seen in historical dogs given two postgrafting immunosuppressive drugs...
  32. ncbi Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  33. ncbi Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Biol Blood Marrow Transplant 12:697-702. 2006
    ..The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions...
  34. pmc The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation
    Zejing Wang
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Br J Haematol 149:101-10. 2010
    ..ABO incompatibility did not affect nonmyeloablative HCT outcomes...
  35. ncbi Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation
    Chirag R Parikh
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Am J Kidney Dis 45:502-9. 2005
    ..The present study compares the incidence of ARF between patients undergoing concurrent myeloablative and nonmyeloablative HCT in the same period at the same institution...
  36. ncbi Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia
    Mohamed L Sorror
    Biol Blood Marrow Transplant 11:814-5. 2005
  37. pmc Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    University of Liege, Liege, Belgium
    Biol Blood Marrow Transplant 13:1041-8. 2007
    ..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning...
  38. ncbi Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease
    Mohamed L Sorror
    Biol Blood Marrow Transplant 11:567-8. 2005

Research Grants2

  1. Impact of Comorbidities on Outcomes of Allogeneic Transplantation
    Mohamed Sorror; Fiscal Year: 2007
    ..End of Abstract) ..